Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on X:
“At the 2025 National Immune Cell Effector Therapy ICE_T conference, Muhammad Umair Mushtaq (Abu Mikael) presented on the current state of tumor-infiltrating lymphocyte (TIL) therapy in metastatic melanoma with Cancer Netwrk: At 4 years, about 20% of patients with advanced melanoma who received TIL therapy were alive and responding to treatment.”
More posts featuring Al-Ola A Abdallah.